万维提示：
1、投稿方式：在线投稿。
2、期刊网址：https://www.springer.com/journal/10384
3、投稿网址：https://www.editorialmanager.com/jjoo/
4、官网邮箱：jjo@po.nichigan.or.jp（编辑部）
更多相关咨询邮箱如下。
5、期刊刊期：双月刊，逢单月出版。
2021年7月17日星期六
期刊相关咨询邮箱【官网信息】
Contact the journal
Submission-related enquiries
Queries about submission issues, peer review process, or the status of your manuscript should be sent to Jayashree Kamaraj (Jayashree.Kamaraj@springernature.com).
Production-related enquiries
Queries about accepted manuscripts in production or post-publication corrections should be sent to Aravindhan Jeyaraj (Aravindhan.Jeyaraj@springer.com).
Rights and Permissions enquiries
For permission requests to reuse or reprint content, please follow the link ‘Rights and permissions’ on the relevant article page. For other queries, contact journalpermissions@springernature.com.
Publication-related enquiries
Queries related to journal publishing should be sent to Sachiko Hayakawa (sachiko.hayakawa@springer.com).
投稿须知【官网信息】
Submission guidelines
Instructions for Authors
The Japanese Journal of Ophthalmology (JJO) is a peer-reviewed scientific journal that publishes manuscripts describing both clinical and basic science research in ophthalmology and vision science. Manuscripts must describe original data that have not been previously published in print or any format, and are not being simultaneously submitted for publication elsewhere. Manuscripts that adhere to the JJO Instructions for Authors and are deemed appropriate for the scope of the journal are sent to reviewers who are specialists in the field. Reviewer comments are then used to determine the suitability of the submission by the JJO Executive Editorial Board. The final decision for all submitted manuscripts rests with the Editor-in-Chief.
GENERAL INFORMATION
(1) Conflicts of interest
All authors are required to disclose conflicts of interest that may have influenced their research, or the preparation and writing of their manuscript, using the International Committee of Medical Journal Editors (ICMJE) Conflict of Interest Disclosure Form downloadable as a PDF file from http://www.icmje.org/coi_instructions.html. The corresponding author is responsible for collecting the ICMJE Conflict of Interest Disclosure Form file from each author, and uploading them at the time of online manuscript submission. If a submitted manuscript is accepted, all information on the conflict of interest disclosure forms will be made public at the time of publication, with the exception of information that the JJO Editorial Board deems irrelevant to the submitted work. Note that research support (e.g. JSPS KAKENHI) should be denoted in the Fund Ref. separately and acknowledged separately in the Acknowledgment section (see “Acknowledgements”).
(2) Institutional review board (IRB)/ethics committee approval for human studies
When a study involves human subjects and/or human-derived materials, authors must adhere to the following and include appropriate statements in the Patients and Methods (or Materials and Methods) section.
• Informed consent must be obtained from each patient after full explanation of the nature and possible consequences of the study and a statement explaining that informed consent was obtained must be included.
• The study must be filed with the appropriate Institutional Review Board (IRB)/Ethics Committee, and a statement explaining either that IRB/Ethics Committee approval has been obtained, or that the IRB/Ethics Committee has ruled that approval was not required for the study must be included. The JJO Editorial Board may request evidence for IRB/Ethics Committee approval (or waiver of such approval) at any time during the submission process, and therefore authors should retain written evidence of such.
• The tenets of the Declaration of Helsinki must be followed where applicable, and a statement that this was done must be included.
(3) Animal studies
If the research involves experimental animals, authors must adhere to the following and include appropriate statements in the Materials and Methods section.
• The study must adhere to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research, and a statement that this was done must be included.
• The study must be approved by the appropriate institutional Animal Care and Use Committee, and a statement explaining that such approval was obtained must be included.
(4) Copyright transfer
The Japanese Ophthalmological Society retains the copyright to all material published in the Japanese Journal of Ophthalmology. A Copyright Transfer Agreement may be downloaded at http://www.springer.com/10384 and must be signed by all authors. A scanned file (PDF) of the signed Copyright Transfer Agreement may then be uploaded at the time of initial online submission of the manuscript.
The Copyright Transfer Agreement must be received by the JJO Editorial Office before any action can be taken regarding the manuscript.
(5) Authorship
All authors should have been directly involved in the work described in the manuscript. Other contributors to a manuscript, such as professors or others who gave helpful advice or companies that donated materials, may be thanked in an Acknowledgments section at the end of the main text. The JJO does not permit two or more authors to be "equal contributors" to a manuscript and, once a manuscript has been submitted, changes or additions of authors are not permitted.
An Authorship Form signed by each author must be submitted to the JJO Editorial Office at the time of initial submission. The form may be downloaded at http://www.springer.com/10384t, and a scanned file (PDF, TIFF, or JPEG) of the signed form may be uploaded at the time of initial online submission of the manuscript.
(6) Content responsibility
All authors must take full responsibility for the content and scientific accuracy of their manuscript as well as of any electronic supplementary materials. No responsibility will be assumed by the Japanese Journal of Ophthalmology, the Japanese Ophthalmological Society, or Springer Japan for any legal claim arising from injury and/or damage to persons or property due to a matter of product liability, negligence, or other circumstances; nor from any use or operation of any methods, products, instructions, or ideas contained in the published material. No test or procedure should be carried out unless the reader judges it to be safe. Independent verification of all diagnoses, drug dosages and treatment should be performed. Discussions, views, and recommendations regarding medical procedures, choice of drugs, and drug dosages are the sole responsibility of the authors.
(7) Multicenter clinical trials
The JJO welcomes the submission of manuscripts reporting results of multicenter clinical trials. These manuscripts may be submitted with authorship in one of the following styles:
• The name of a study group only (collective authorship)
• The names of individuals of a writing committee and the name of a study group
In each case, one individual must serve as the corresponding author and individuals named as authors must have been specifically involved in the preparation of the manuscript. The ICMJE Conflict of Interest Disclosure Form, the Copyright Transfer Agreement, and the Authorship Form must be completed, signed and submitted for each author. All individuals and institutions involved in the clinical trial may be acknowledged as a list of investigators under a separate heading of Study Group Investigators.
Copyright Transfer and Authorship Form PDF (Download pdf, 157 kB)
TYPES OF ARTICLES
(1) Clinical or laboratory investigations
The article should be no more than 6000 words in length (including references and tables), and should be arranged as follows; Introduction, Materials and Methods (or Subjects and Methods), Results, and Discussion. The JJO has discontinued the category of Case Reports. However, if a manuscript describes a single case that involves a novel finding or novel treatment, and contains significant detail for that case (e.g., including pathological analysis), the manuscript may be considered as a full-length article. For such article type of case reports, the articles should be arranged as follows; Introduction, Case report(s), and Comments or Discussion.
(2) Review articles
Review articles are published generally by invitation of the Editor-in-Chief. However, unsolicited manuscripts will be considered, and interested authors should first contact the JJO Editorial Office regarding the possibility of a submission.
(3) Readers’ comments
In addition to full-length articles on original research, The JJO will also consider Readers’ Comments specifically pertaining to articles published in the JJO, subject to editorial review and space availability.
MANUSCRIPT PREPARATION AND SUBMISSION
All manuscripts must conform to the language and writing style of the JJO. This includes submission of the manuscript in correct medical English as well as submission of any figures and tables in the formats specified. Use the checklist downloaded at http://www.springer.com/10384 to ensure that your submission is complete and in compliance with the JJO Instructions for Authors.
Definition of Prior Publication
Prior publication includes information that has been released into the public domain, via either print or electronic media.
At the time of manuscript submission, authors must submit to the editor-in-chief copies of any papers, reports, or other articles containing the same or substantially similar content or data to those of the manuscript, and must include information on the medium—print or electronic—through which the materials were released to the public. The editor-in-chief will then determine whether the work constitutes a prior publication.
Each author has the responsibility and duty to submit to the editor-in-chief copies of all research content and data that have previously been released into the public domain (for example, those posted on a preprint server). After manuscript submission, any material containing the same or substantially similar content to the manuscript that is found to have been disseminated, in ANY manner, without prior notice will be immediately rejected.
(1) Permission for previously published items
All figures, tables, and text passages that have been previously published require permission from the copyright owner(s) for both the print and online editions of the JJO. All expenses related to obtaining such permission must be borne by the authors. By signing the Copyright Transfer Agreement, you attest that you own the copyright to the original material in your article and that appropriate permission has been obtained for previously published materials. Permission must be obtained for any material to which the authors do not own full copyright. Materials such as clinical images, photos, graphs or images of devices obtained from companies cannot be published without such permission.
If the copyright owner replies that permission has been granted, include evidence that such permission has been granted when submitting your manuscript. A copy of the permission must be sent to the JJO Editorial Office with your manuscript number and a description of the materials in question. Any material received without such evidence will be assumed to originate from the authors. In the manuscript, the copyright owner should be correctly credited in figure legends or table explanations (see “Tables” and “Figures”).
(2) Professional medical English editing
Authors may choose to utilize professional medical English editors in the preparation of their manuscript. The name of the professional editor or editing company employed should be noted in an Acknowledgments section at the end of the main text (see “Acknowledgements”).
(3) Online submission
Authors should submit their manuscript and accompanying material to the JJO via the online Editorial Manager system by logging on to http://jjoo.edmgr.com and uploading all manuscript files. Once you have entered Editorial Manager, assistance can be found by clicking on “Help” in the upper left corner.
(4) Title page
The first page of the manuscript should be a title page containing information in the following order:
• Manuscript title (sentences and abbreviations are not allowed)
• Running title of no more than 40 characters including spaces
• Full names of all authors
• Institutional affiliations of all authors
• Postal address, telephone and fax numbers, and e-mail address of the corresponding author (only 1 author can serve as the corresponding author)
• Word counts for the abstract and the main text (body of the manuscript)
• Number of references, number of figures, and number of tables
(5) Abstract
Provide a structured abstract of no more than 250 words. For clinical or laboratory investigations, the abstract should be divided into Purpose, Study Design (e.g. retrospective, prospective, clinical and experimental), Methods, Results, and Conclusion. The abstract should not contain any undefined abbreviations or references.
(6) Keywords
Keywords are required for indexing and abstracting services. Up to five words should be listed on a separate page.
(7) Main text
• Formatting
Manuscripts should be created using Microsoft Word and be double-spaced with 2.5-cm margins on all sides. Pages should be numbered consecutively, with consecutive line numbering from the first through the last page using the automatic numbering functions in the software. The recommended font is Times New Roman. Do not use field functions. For indenting use tab stops, not the space bar. For tables use the table function, not spreadsheets. For equations use either the equation editor or MathType.
• Headings and subheadings
Use no more than three levels of headings.
• American Medical Association's Manual of Style（AMA manual of Style）
Authors may consult American Medical Association's Manual of Style: A Guide for Authors and Editors (Iverson C, Christiansen S, Flanagin A, et al. 10th ed. New York: Oxford University Press, 2007).
• Abbreviations
Abbreviations must be defined at first use in the Abstract and again in the main text, and in each figure or table. Only commonly accepted abbreviations should be used as stated in the American Medical Association's Manual of Style（AMA manual of Style）. Drug and chemical names should be stated using generic or standard chemical nomenclature.
• Units of measurement
Units of measurement should conform to the International System (SI) with the exception of clinical data for which conventional units are deemed more appropriate.
• Reporting visual acuity
Visual acuity should be reported in the original units used for measurements, whether decimal, Snellen, or Early Treatment of Diabetic Retinopathy Study (ETDRS) units. However, means and medians should be calculated only after conversion to logarithm of the minimum angle of resolution (logMAR) units with a statement describing such calculations in the Methods section.
(8) Acknowledgments
The Acknowledgments section should follow the main text. If data from other published sources are used, the authors must obtain permission as explained above and state full acknowledgment as indicated by the copyright owners. Acknowledgments should also be made of research grants (e.g., JSPS KAKENHI), technicians and colleagues who assisted in the study, individuals or companies who provided materials, mentors who provided advice and encouragement, and professional medical English editing. For multicenter clinical trials, all individuals and institutions involved in the trials may be acknowledged as a list of investigators under a separate heading of Study Group Investigators (See “Multicenter clinical trials”). Conflicts of interest should not be stated in the Acknowledgements section (see “Conflicts of interest”).
(9) References
Reference citations in the text should be identified by numbers in square brackets before the punctuation mark. Some examples:
Negotiation research spans many disciplines [3].
This result was later contradicted by Becker and Seligman [5].
This effect has been widely studied [1–3, 7].
……
更多详情：
https://www.springer.com/journal/10384/submission-guidelines
